Lurbinectedin is a drug used to treat small cell lung cancer (SCLC) and has been recently approved by the US Food and Drug Administration (FDA) for this indication [1]. While there are no reports of toxicity with lurbinectedin in the sources provided, the drug has been associated with some side effects, including nausea, fatigue, decreased appetite, vomiting, constipation, and anemia [2].

A recent study published in the Journal of Thoracic Oncology evaluated the efficacy and safety of lurbinectedin in patients with SCLC. The study reported that lurbinectedin was well-tolerated, with manageable toxicities [2]. Another study reported that the combination of lurbinectedin and doxorubicin was effective in treating SCLC, but the primary endpoint was not met [3].

In conclusion, while there are no reports of toxicity with lurbinectedin in the sources provided, the drug has been associated with some side effects, including nausea, fatigue, decreased appetite, vomiting, constipation, and anemia. Lurbinectedin has been shown to be well-tolerated, with manageable toxicities, in studies evaluating its efficacy and safety in patients with SCLC.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://journals.sagepub.com/doi/full/10.1177/17588359211020529
[3] https://ascopost.com/issues/october-10-2021/benefits-seen-with-lurbinectedin-plus-doxorubicin-in-small-cell-lung-cancer-but-primary-endpoint-missed/